Transaction Overview
Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced that on Thursday, 13 June 2026, it closed a private placement that generated approximately $4 million in gross proceeds before fees and expenses. The transaction was executed through the sale of 3,883,496 shares of common stock or pre‑funded warrants at $1.03 per share, representing a capital raise that is notable relative to the company’s market capitalization of $2.08 million.
Offering Details
The placement incorporated two preferred investment options, designated Series A‑1 and Series A‑2, each granting the holder the right to purchase up to 3,883,496 shares of common stock. Both series carry an exercise price of $0.91 per share. Series A‑1 options become exercisable only after stockholder approval of the share issuance and will expire five years after the approval date. Series A‑2 options are immediately exercisable and will expire 24 months from the effective date of the resale registration statement. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Use of Proceeds and Financial Position
Arcadia stated that the net proceeds will be used for working capital and general corporate purposes. The company highlighted a current ratio of 3.79, indicating solid short‑term liquidity. Independent analysis from InvestingPro classified the stock as undervalued at current levels.
Regulatory and Compliance Framework
The securities were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and therefore were not registered with the SEC at the time of issuance. Arcadia committed to filing registration statements with the SEC to facilitate the resale of the unregistered securities issued in this private placement.
Business Context
Arcadia Biosciences produces and markets wellness products. Its 2025 Form 10‑K disclosed that the company may require additional funding to sustain operations and planned activities, underscoring the strategic importance of the current capital raise.
Auditor Change
In a concurrent development, Arcadia announced the dismissal of Deloitte & Touche LLP as its independent registered public accounting firm and the appointment of Ramirez Jimenez International CPAs (RJI) as the new auditor. The change will take effect beginning with the review of the financial statements for the quarter ending 31 March 2026. Deloitte’s prior audit reports contained no adverse opinions or disclaimers, though an explanatory paragraph noted the company’s financial challenges.
Additional Notes
The article was generated with AI assistance and reviewed by an editor. All figures, dates, and terms are presented exactly as disclosed in the source material.